首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Expert Opinion On Investigational Drugs

Expert Opinion On Investigational Drugs杂志,由Taylor and Francis Ltd.出版,于1994年创刊,Monthly,出版语言English,ISSN:1354-3784,E-ISSN:1744-7658。

投稿咨询
Expert Opinion On Investigational Drugs
Expert Opinion On Investigational Drugs
Expert Opinion On Investigational Drugs
SCI SCIE

杂志介绍

JCR分区
Q2
中科院分区
3区
影响因子
4.3
CiteScore
8.5
期刊收录
SCI、SCIE

Expert Opinion On Investigational Drugs(中文译名:《研究药物专家意见》),ISSN:1354-3784,EISSN:1744-7658,是Taylor and Francis Ltd.出版的国际性学术期刊,创刊于1994年,以Monthly形式稳定发行,2026年总发文量约73篇。该刊采用非OA开放访问,学科归属为医学 - 药学。该刊是医学、药学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达4.3,2025年期刊CiteScore为8.5,2025年期刊自引率约0%,在中科院期刊分区体系中位列医学大类3区,在所属学科领域具备高学术影响力与国际认可度。Expert Opinion On Investigational Drugs长期聚焦医学、药学及相关产业的技术应用前沿,平均审稿周期较慢,6-12周,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、药学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USAItaly、England、GERMANY (FED REP GER)、Canada、Australia、CHINA MAINLAND等为核心发文国家与地区;UNIVERSITY OF TEXAS SYSTEMHARVARD UNIVERSITY、UNIVERSITY OF GENOA、INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)、MAYO CLINIC、IRCCS OSPED POLICLIN SAN MARTINO、UNIVERSITY OF NAPLES FEDERICO II等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
PHARMACOLOGY & PHARMACY 药学
3区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
PHARMACOLOGY & PHARMACY 药学
2区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
PHARMACOLOGY & PHARMACY 药学
2区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:PHARMACOLOGY & PHARMACY SCIE Q2 95 / 356

73.5

学科:PHARMACOLOGY & PHARMACY SCIE Q2 157 / 356

56.04

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:PHARMACOLOGY & PHARMACY SCIE Q1 79 / 352

77.7

学科:PHARMACOLOGY & PHARMACY SCIE Q2 89 / 353

74.93


中国学者近期发文

1
The latest investigational drugs for patients with allergic rhiniti

Author:Fang, Dandan; Zhang, Yuan; Zhang, Luo

Journal: EXPERT OPINION ON INVESTIGATIONAL DRUGS. 2026; Vol. , Issue , pp. -. DOI: 10.1080/13543784.2025.2612328

2
Safety, pharmacokinetics, and efficacy of HY-072808 ointment, a novel PDE4 inhibitor, in adolescent and adult patients with mild-to-moderate A

Author:Yao, Feng; He, Mingchao; Wang, Jing; Li, Yao; Zhang, Qian; Yang, Jingjing; Wu, Jingying; Zhang, Qin; Zhou, Renpeng; Zhang, Meiling; Meng, Linying; Wu, Liming; Chu, Zhaoxing; Hu, Wei

Journal: EXPERT OPINION ON INVESTIGATIONAL DRUGS. 2025; Vol. 34, Issue 5, pp. 435-447. DOI: 10.1080/13543784.2025.2510671

3
Safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR-2010, a novel anti-MASP-2 antibody, in healthy volunteers: a randomized, double-blind, placebo-controlled phase 1 stud

Author:Lin, Pingping; Wang, Chenjing; Hu, Xiaotong; Fang, Lin; Lin, Hongda; Sun, Feifei; Huang, Rong; Ban, Rongxin; Feng, Sheng; Gao, Zhenyan; Shen, Kai; Cao, Yu

Journal: EXPERT OPINION ON INVESTIGATIONAL DRUGS. 2025; Vol. 34, Issue 4, pp. 339-348. DOI: 10.1080/13543784.2025.2500291

4
A phase 1, randomized, double-blind, placebo-controlled trial investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of KN056 (a recombinant human GLP-1 variant Fc fusion protein) in healthy Chinese participant

Author:Qin, Yuan-Fang; Zhang, Wen-Hua; Zhang, Hao-Nan; Li, Yu-Wei; Huang, Wen-Qiao; Xie, Jin-Lian; Yang, Shuang; Li, Lan-Ni; Cui, Chang; Pei, Qi; Huang, Jie; Yang, Guo-Ping

Journal: EXPERT OPINION ON INVESTIGATIONAL DRUGS. 2025; Vol. 34, Issue 4, pp. 329-337. DOI: 10.1080/13543784.2025.2500303

5
Evaluation of pharmacokinetic and pharmacodynamic similarity of an IDegAsp biosimilar versus the originator in healthy Chinese volunteer

Author:Liu, Hui; Xiong, Yang; Chen, Xinlei; Yu, Hongling; Lan, Li; He, Wengang; Wang, Wenjia; Zhuang, Yulei; Deng, Li; Huang, Kanghua; Guo, Linfeng; Yu, Yerong

Journal: EXPERT OPINION ON INVESTIGATIONAL DRUGS. 2025; Vol. 34, Issue 1-2, pp. 97-104. DOI: 10.1080/13543784.2025.2463085

6
First-in-human study on tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of XKH001, a recombinant humanized monoclonal antibody against IL-25 in healthy Chinese volunteer

Author:Zhang, Hong; Zheng, Wenbo; Peng, Ran; Wu, Dandan; Hu, Yue; Sun, Tiantian; Gao, Lei; Liu, Yusi; Guo, Li; Ding, Yanhua; Liu, Li

Journal: EXPERT OPINION ON INVESTIGATIONAL DRUGS. 2025; Vol. , Issue , pp. -. DOI: 10.1080/13543784.2025.2453162


在线咨询

Expert Opinion On Investigational Drugs

国际简称:EXPERT OPIN INV DRUG参考译名:研究药物专家意见

年发文量:73 CiteScore:8.5 是否预警:否 Gold OA文章占比:5.47% 研究类文章占比:35.62%

杂志社联系方式:INFORMA HEALTHCARE, TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON, ENGLAND, EC2A 4LQ

Expert Opinion On Investigational Drugs